The Study on the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04810793

Enrollment

820

Registered

2021-03-23

Start date

2020-07-01

Completion date

2022-06-30

Last updated

2022-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter Pylori

Keywords

Re-eradication time, Remedial treatment

Brief summary

The patients who accepted the quadruple eradication program of the helicobacter pylori but failed to eradicate helicobacter pylori will be assessed the most suitable re-eradication time of helicobacter pylori.

Detailed description

Helicobacter pylori (HP) infection is a common global infectious disease, which is an important cause of chronic gastritis, peptic ulcer and gastric cancer. At present, due to the non-standard Helicobacter pylori eradication program in clinical work, poor patient compliance and other reasons, the phenomenon of HP eradication treatment failure is more and more common. However, there is still no conclusion on the most appropriate time for remedial treatment in patients with Hp eradication failure.

Interventions

DRUGAmoxicillin , Levofloxacin and Esomeprazole

Esomeprazole-Bismuth-Amoxicillin-Levofloxacin-containing quadruple regimens

DRUGAmoxicillin , Furazolidone and Esomeprazole

Esomeprazole-Bismuth-Amoxicillin-Furazolidone-containing quadruple regimens

DRUGTetracycline , Furazolidone and Esomeprazole

Esomeprazole-Bismuth-Tetracycline-Furazolidone-containing quadruple regimens

DRUGAmoxicillin,Levofloxacin and Vonoprazan fumarate

Amoxicillin-Levofloxacin-Vonoprazan fumarate-containing quadruple group

DRUGAmoxicillin,Furazolidone and Vonoprazan fumarate

Amoxicillin-Furazolidone-Vonoprazan fumarate-containing quadruple group

DRUGTetracycline,Furazolidone and Vonoprazan fumarate

Tetracycline-Furazolidone-Vonoprazan fumarate-containing quadruple group

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* Patients, aged between 18 and 70 years old, with positive H. pylori infection that was eradicated by previous therapies but failed are included. The H. pylori infection is confirmed by the positive rapid urease test or 13C-breath test.

Exclusion criteria

* Patients with significant underlying disease including liver, cardiac, pulmonary, and renal diseases, neoplasia, coagulopathy and genetic diseases, history of gastric surgery, pregnancy, breast-feeding, active gastrointestinal bleeding, the use of PPI, NSAID or antibiotics during the 4 weeks prior to enrolment, and previous history of allergic reactions to any of the medications used in this protocol. Patients previously treated with H. pylori eradication regimens or those unwilling to participate in the study were also excluded.

Design outcomes

Primary

Measure	Time frame	Description
The most suitable re-eradication time	1year	The most suitable re-eradication time will be assessed by paired comparison method .

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026